S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
New "Mined in America" Lithium Opportunities? (Ad)
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
AI-powered IoT Automation is Driving Samsara To New Highs
New "Mined in America" Lithium Opportunities? (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
New "Mined in America" Lithium Opportunities? (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
New "Mined in America" Lithium Opportunities? (Ad)
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
AI-powered IoT Automation is Driving Samsara To New Highs
New "Mined in America" Lithium Opportunities? (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
New "Mined in America" Lithium Opportunities? (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
New "Mined in America" Lithium Opportunities? (Ad)
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
AI-powered IoT Automation is Driving Samsara To New Highs
New "Mined in America" Lithium Opportunities? (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
New "Mined in America" Lithium Opportunities? (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
New "Mined in America" Lithium Opportunities? (Ad)
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
AI-powered IoT Automation is Driving Samsara To New Highs
New "Mined in America" Lithium Opportunities? (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
New "Mined in America" Lithium Opportunities? (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

$40.55
-2.78 (-6.42%)
(As of 06/7/2023 ET)
Compare
Today's Range
$40.24
$41.59
50-Day Range
$34.73
$43.33
52-Week Range
$32.69
$48.82
Volume
5.55 million shs
Average Volume
1.13 million shs
Market Capitalization
$5.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.64

Ionis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
15.0% Upside
$46.64 Price Target
Short Interest
Bearish
5.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.34mentions of Ionis Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$286,134 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.54) to ($3.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

802nd out of 981 stocks

Pharmaceutical Preparations Industry

399th out of 477 stocks


IONS stock logo

About Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
I've Got My Eye On Ionis Pharmaceuticals for Higher Highs
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
8-K: IONIS PHARMACEUTICALS INC
See More Headlines

IONS Price History

IONS Company Calendar

Last Earnings
5/03/2023
Today
6/07/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.64
High Stock Price Forecast
$67.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+15.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Net Income
$-269,720,000.00
Pretax Margin
-53.18%

Debt

Sales & Book Value

Annual Sales
$575.97 million
Book Value
$4.03 per share

Miscellaneous

Free Float
139,723,000
Market Cap
$5.80 billion
Optionable
Optionable
Beta
0.53

Key Executives

  • Brett P. MoniaBrett P. Monia
    Chief Executive Officer & Director
  • Onaiza Cadoret-Manier
    EVP, Chief Product Strategy & Operations Officer
  • Elizabeth L. HougenElizabeth L. Hougen
    Chief Financial Officer & Executive VP-Finance
  • C. Frank Bennett
    Chief Scientific Officer & Executive VP
  • Sanjay Bhanot
    Chief Medical Officer & SVP













IONS Stock - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price forecast for 2023?

10 analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $67.00. On average, they expect the company's share price to reach $46.64 in the next year. This suggests a possible upside of 15.0% from the stock's current price.
View analysts price targets for IONS
or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2023?

Ionis Pharmaceuticals' stock was trading at $37.77 on January 1st, 2023. Since then, IONS stock has increased by 7.4% and is now trading at $40.55.
View the best growth stocks for 2023 here
.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our IONS earnings forecast
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.13. The firm had revenue of $131 million for the quarter, compared to the consensus estimate of $126.88 million. Ionis Pharmaceuticals had a negative net margin of 56.85% and a negative trailing twelve-month return on equity of 57.58%. The business's quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.46) earnings per share.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $597.65 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Clearbridge Investments LLC (3.77%), Price T Rowe Associates Inc. MD (2.75%), ARK Investment Management LLC (1.84%), BVF Inc. IL (1.79%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $40.55.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.80 billion and generates $575.97 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

The company employs 660 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.

This page (NASDAQ:IONS) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -